Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00583947 · ClinicalTrials.gov registry record · Phase 2

A Safety and Tolerability Study of Arformoterol Tartrate Inhalation Solution in Pediatric Subjects

A Phase 2 study, sponsored by Sumitomo Pharma America.

Completed
Registry status
Phase 2
Development phase
53
Enrollment target

NCT00583947 is a Phase 2 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 53 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00583947, a Phase 2 study, has completed, sponsored by Sumitomo Pharma America.

COMPLETED
Registry status
Phase 2
Development phase
53 participants
Enrollment target

Study Summary

To determine the safety and tolerability of Arformoterol Tartrate in children with asthma

Interventions

  • DRUG levalbuterol
  • DRUG arformoterol

Trial Details

FieldValue
Enrollment Target 53 participants
Start Date 2008-01
Est. Completion 2008-12
Phase Phase 2

Sponsor

Sumitomo Pharma America

168 total trials

What the Registry Record Tells You About NCT00583947

The ClinicalTrials.gov registry entry for NCT00583947 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which levalbuterol is the first listed.

NCT00583947 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00583947 about?

NCT00583947 is a clinical study titled "A Safety and Tolerability Study of Arformoterol Tartrate Inhalation Solution in Pediatric Subjects". To determine the safety and tolerability of Arformoterol Tartrate in children with asthma

What is the current status of trial NCT00583947?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2008-01. Estimated completion is 2008-12.

What interventions are being tested in trial NCT00583947?

The interventions under investigation include: levalbuterol (DRUG), arformoterol (DRUG).

Who is sponsoring clinical trial NCT00583947?

This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.